Please use this identifier to cite or link to this item:
Title: Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms.
Authors: Torrens, Gabriel
Cabot, Gabriel
Ocampo-Sosa, Alain A
Conejo, M Carmen
Zamorano, Laura
Navarro, Ferrán
Pascual, Álvaro
Martínez-Martínez, Luis
Oliver, Antonio
metadata.dc.subject.mesh: Azabicyclo Compounds
Drug Combinations
Microbial Sensitivity Tests
Pseudomonas aeruginosa
beta-Lactam Resistance
Issue Date: 23-Sep-2016
Abstract: The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at ≤4 μg/ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant β-lactam resistance mechanisms.
metadata.dc.identifier.doi: 10.1128/AAC.01282-16
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.